Navigation Links
Lilly Caps Successful Year with Strong Fourth-Quarter Results
Date:1/29/2008

$156.8 million of sales, essentially flat when compared with the fourth quarter of 2006. U.S. sales decreased 7 percent to $126.1 million, due to a decline in demand. Sales outside the U.S. increased 49 percent to $30.6 million, due primarily to higher demand and the favorable impact of foreign exchange rates.

For the full year of 2007, worldwide Strattera sales decreased 2 percent, to $569.4 million. U.S. Strattera sales for 2007 were $464.6 million, a 9 percent decrease driven by lower demand. Strattera sales outside the U.S. were $104.8 million, a 50 percent increase, driven by increased demand and favorable exchange rates.

Other Diabetes Care Products

As previously disclosed, Lilly's U.S. marketing rights with respect to Actos(R) expired in September 2006; however, Lilly will continue to receive royalties from Takeda Pharmaceuticals North America at a declining rate through September 2009. Lilly continues to market the product in many countries outside the U.S. In the fourth quarter, Actos generated $93.2 million of revenue for Lilly, the majority of which was outside the U.S. Actos revenue increased 4 percent versus the fourth quarter of 2006. For the full-year 2007, Actos generated $370.6 million of revenue for Lilly, a decrease of 17 percent versus 2006, reflecting the declining royalty rate from U.S. Actos sales.

Worldwide sales of Byetta were $183.6 million in the fourth quarter, a 34 percent increase compared with the fourth quarter of 2006. U.S. Byetta sales grew 29 percent to $176.3 million. Byetta sales outside the U.S. were $7.3 million. Lilly reports as revenue its 50 percent share of Byetta's gross margin in the U.S., 100 percent of Byetta sales outside the U.S., and its sales of Byetta pen delivery devices to its partner, Amylin Pharmaceuticals. For the fourth quarter, Lilly recognized revenue totaling $92.1 million, representing a 34 percent increase compared with the fourth quarter of 2006.

For the full year of
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. Lilly Sets Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results Announcement
2. Lilly Announces Dividend Increase
3. Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
4. International Federation-Lilly Agreement Will Allow Significant Increase in MDR-TB Programmes
5. JDRF and Lilly partner to fund research to identify beta cell biomarkers
6. The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa
7. Lilly Contributes $10.8 Million to United Way Annual Campaign
8. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
9. Lilly Sets Date and Time for American Heart Association Conference Call
10. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
11. Eli Lilly and Company Aids California Recovery Effort
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Sterilizers manufacturers and is a valuable source of guidance ... industry. This report provides a basic overview of the ... this part, the report presents the company profile, product ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast and ... landscape, unmet needs, current pipeline and commercial opportunities in ... which is typically used for treating colorectal cancer. It ... gastric cancer and pancreatic cancer. TS-1 is composed of ... approved in 1999 in Japan for the treatment of ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... on the human genome project , which is ... the genes will enable one to have the information to ... even skin. It will also help say whether a cell ... in the womb for diseases, and device specific advancements against ...
... published in the December issue of the Journal ... in peripheral blood mononuclear cells (PBMCs) from individuals ... infected patients treated with antifilarial agents. According ... the National Institute of Allergy and Infectious Diseases ...
... the heart attack patients should get an immediate procedures to ... , ,Cleveland Clinic cardiologist, Dr. Deepak Bhatt analyzed medical ... that patients whose white blood cell count is in what ... risk of death after a heart attack than patients with ...
... Lewy body disease, and Multiple System Arophy - ... symptomatic due to a deficiency of a specific ... is dopamine. When the neurons that produce these ... oxidation, the eventual results are tremors and sometimes ...
... to diagnose and many a times the diagnosis is ... emerging as a promising technique for early diagnosis of ... facilitating rapid amplification of small amounts of a genome ... Urology Congress in India. Presence of even one ...
... ingredient found in many non-prescription cough and cold medications. ... risk of stroke by 23 percent. Dr.Ralph I. Horwitz, ... have linked exposure to PPA to the occurrence of ... results when an artery wall ruptures and prevents blood ...
Cached Medicine News:
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
(Date:12/24/2014)... Dec. 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... is proud to announce Jennifer Hagerman , Pharm.D., ... will take office as the president of the Michigan ... ceremony will take place Feb. 28, 2015, at the ... at the Renaissance Center in Detroit, Michigan ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... Show Superior Decrease in Pain Scores Compared to Saline ... the results of a six-month safety and efficacy study ... decreasing the pain of knee osteoarthritis (OA) at 26 ... superior to saline in decreasing pain at 26 weeks ...
... Phase 3 Avanafil Study REVIVE (TA-301) is Complete MOUNTAIN ... VVUS ), a biopharmaceutical company developing innovative, next-generation ... sexual health, today announced that it has initiated an ... avanafil, in males with erectile dysfunction (ED). VIVUS ...
Cached Medicine Technology:Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain 2Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain 3VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 2VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction 3
Designed to give maximum drying area while taking up minimal bench space....
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm....
Thermostatically controlled, large capacity surface to quickly evaporate water and solvents from slides and mounting media....
Compact instrument that quickly dries racks of slides using warm air....
Medicine Products: